Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population

Michael Clearfield, Edwin J. Whitney, Stephen Weis, John R. Downs, Deborah R. Shapiro, Evan A. Stein, Douglas J. Watson, Alexandra Langendörfer, Polly A. Beere, Jeremiah Stamler, Antonio M. Gotto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalJournal of Cardiovascular Risk
Volume7
Issue number2
StatePublished - 4 Jul 2000

Fingerprint

Coronary Artery Disease
Cholesterol
Air
Lovastatin
Cohort Studies
Placebos
HDL Cholesterol
Population
Diet Therapy
Fat-Restricted Diet
Nutrition Surveys
Primary Prevention
Hispanic Americans
LDL Cholesterol
Life Style
Triglycerides
Cardiovascular Diseases
Demography
Lipids
Therapeutics

Keywords

  • Cholesterol
  • Controlled clinical trials
  • Lovastatin
  • Primary prevention

Cite this

Clearfield, M., Whitney, E. J., Weis, S., Downs, J. R., Shapiro, D. R., Stein, E. A., ... Gotto, A. M. (2000). Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population. Journal of Cardiovascular Risk, 7(2), 125-133.
Clearfield, Michael ; Whitney, Edwin J. ; Weis, Stephen ; Downs, John R. ; Shapiro, Deborah R. ; Stein, Evan A. ; Watson, Douglas J. ; Langendörfer, Alexandra ; Beere, Polly A. ; Stamler, Jeremiah ; Gotto, Antonio M. / Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS) : Baseline Characteristics and comparison with USA population. In: Journal of Cardiovascular Risk. 2000 ; Vol. 7, No. 2. pp. 125-133.
@article{28380af393b249d680ae2d34856d6334,
title = "Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population",
abstract = "Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85{\%}) and 997 women (15{\%}) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89{\%} white, 7{\%} Hispanic, and 3{\%} black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Cholesterol, Controlled clinical trials, Lovastatin, Primary prevention",
author = "Michael Clearfield and Whitney, {Edwin J.} and Stephen Weis and Downs, {John R.} and Shapiro, {Deborah R.} and Stein, {Evan A.} and Watson, {Douglas J.} and Alexandra Langend{\"o}rfer and Beere, {Polly A.} and Jeremiah Stamler and Gotto, {Antonio M.}",
year = "2000",
month = "7",
day = "4",
language = "English",
volume = "7",
pages = "125--133",
journal = "Journal of Cardiovascular Risk",
issn = "1350-6277",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

Clearfield, M, Whitney, EJ, Weis, S, Downs, JR, Shapiro, DR, Stein, EA, Watson, DJ, Langendörfer, A, Beere, PA, Stamler, J & Gotto, AM 2000, 'Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS): Baseline Characteristics and comparison with USA population', Journal of Cardiovascular Risk, vol. 7, no. 2, pp. 125-133.

Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS) : Baseline Characteristics and comparison with USA population. / Clearfield, Michael; Whitney, Edwin J.; Weis, Stephen; Downs, John R.; Shapiro, Deborah R.; Stein, Evan A.; Watson, Douglas J.; Langendörfer, Alexandra; Beere, Polly A.; Stamler, Jeremiah; Gotto, Antonio M.

In: Journal of Cardiovascular Risk, Vol. 7, No. 2, 04.07.2000, p. 125-133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Air force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TexCAPS)

T2 - Baseline Characteristics and comparison with USA population

AU - Clearfield, Michael

AU - Whitney, Edwin J.

AU - Weis, Stephen

AU - Downs, John R.

AU - Shapiro, Deborah R.

AU - Stein, Evan A.

AU - Watson, Douglas J.

AU - Langendörfer, Alexandra

AU - Beere, Polly A.

AU - Stamler, Jeremiah

AU - Gotto, Antonio M.

PY - 2000/7/4

Y1 - 2000/7/4

N2 - Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

AB - Background: Results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that treatment with lovastatin, in addition to modifications of diet and lifestyle, reduced the rate of first acute major coronary events compared with placebo in a cohort that included participants with average to mildly elevated total levels of cholesterol, and below average levels of high-density lipoprotein cholesterol, women, and elderly subjects. Objective: To describe the baseline characteristics of the study's cohort. Design: This was a double-blind, placebo-controlled, primary-prevention trial in which Americans with average to mildly elevated total levels of cholesterol [4.65-6.83 mmol/l (180-264 mg/dl)] and no clinical evidence of atherosclerotic cardiovascular disease were randomly allocated either 20-40 mg/day lovastatin or placebo in addition to a low-saturated fat, low-cholesterol diet. Baseline characteristics of the study cohort are described, and the characteristics of a USA reference population based upon NHANES III data are provided for comparison. Results: The study includes 5608 men (85%) and 997 women (15%) with mean total cholesterol level 5.71 ± 0.54 mmol/I (221 ± 21 mg/dl), low-density lipoprotein cholesterol level 3.88 ± 0.44 mmol/I (150 ± 17 mg/dl), high- density lipoprotein cholesterol 0.96 ± 0.15 mmol/I (37 ± 6 mg/dl), and median triglyceride level 1.78 ± 0.86 mmol/I (158 ± 76 mg/dl). The mean age is 58 years (ranges 45-73 years for men and 55-73 years for women). The participants are 89% white, 7% Hispanic, and 3% black. Conclusion: Results from AFCAPS/TexCAPS will be applicable to large segments of populations; in the USA alone, eight million share the demographic and baseline-lipid-level characteristics of the study cohort. (C) 2000 Lippincott Williams and Wilkins.

KW - Cholesterol

KW - Controlled clinical trials

KW - Lovastatin

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=84910077025&partnerID=8YFLogxK

M3 - Article

C2 - 10879416

AN - SCOPUS:84910077025

VL - 7

SP - 125

EP - 133

JO - Journal of Cardiovascular Risk

JF - Journal of Cardiovascular Risk

SN - 1350-6277

IS - 2

ER -